The sales are pre-planned 10b5-1 transactions and immaterial in size. Monitor the next 10-Q for any change in the $2.0B buyback execution pace and for further insider activity that deviates from routine plans.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 9 $582.46entry
- T+1 · 7d ago +1.06%α +1.42% · $588.61
- T+5 · 17h ago +0.93%α +2.62% · $587.88
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CEO Martine Rothblatt and EVP Paul Mahon sold shares on November 5, 2026, two days after United Therapeutics reported Q3 revenue above consensus but GAAP EPS below consensus due to a $130M in-process R&D charge. The sales were under 10b5-1 plans and represent a trivial fraction of market cap, making them routine portfolio management rather than a negative signal.
Key Financial Metrics
Key Facts
- CEO Rothblatt sold 320 shares at $562.51 ($180K) under a 10b5-1 plan on Nov 5, 2026
- EVP Mahon sold 78 shares at $596.77 ($47K) under a 10b5-1 plan on Nov 5, 2026
- Total open-market sales in the cluster: $227K, or 0.0009% of $26.1B market cap
- Q3 2026 revenue was $832.5M (+4% YoY), above $781.1M consensus
- GAAP diluted EPS was $5.71, below $6.04 consensus, due to a $130M in-process R&D charge
- Company announced a new $2.0B share repurchase authorization on Nov 4, 2026
Financial Impact
Insider sales of $227K are negligible relative to $26.1B market cap
Risk Factors
- GAAP EPS miss due to acquisition-related charges could pressure near-term sentiment
- Insider sales under 10b5-1 plans are routine and carry no incremental risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1794002108791 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $587.88 Now $587.88 +0.00% settles Nov 24
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Viewing Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers